Gepotidacin mesylateProduct ingredient for Gepotidacin

Gepotidacin is a first-in-class triazaacenaphthylene antibacterial targeting bacterial DNA gyrase and topoisomerase IV.⁸ Its target is similar to that of fluoroquinolone antibacterials - e.g. ciprofloxacin - while being structurally and pharmacologically distinct.⁶ By inhibiting two distinct bacterial enzymes, a lower potential for the development of resistance to gepotidacin is expected.⁷

In March 2025, gepotidacin was approved by the FDA for the treatment of uncomplicated urinary tract infections in select patients.^7,8 In December later the same year, the FDA approved another indication for gepotidacin for the treatment of uncomplicated urogenital gonorrhea. ¹⁰